Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 20 peer-reviewed journal articles Updated
Ophthalmology

Understanding Your Diagnosis: AAION and GCA

At a Glance

AAION is an urgent optic nerve injury, usually caused by giant cell arteritis. Vision loss is often permanent, so doctors start high-dose steroids promptly and use blood tests, imaging, or biopsy while working to protect sight in the other eye.

  • The priority is protecting your remaining vision. The treatment you receive today is designed to save the sight in your unaffected eye.
  • Take steroids exactly as prescribed. Do not wait for test results before starting or continuing your medication.
  • Know who to call. Make sure you leave your appointment with an after-hours phone number to reach your care team if you experience new vision changes.

If you have just been told you have Arteritic Anterior Ischemic Optic Neuropathy (AAION), you are likely feeling a sense of profound shock or panic [1]. You may have experienced a sudden, dramatic drop in vision in one eye, and the speed at which this happened can feel traumatic [2][3]. It is important to know that what you are feeling—fear, grief, and a sense of loss—is a normal response to a life-changing medical event [1][4].

This diagnosis is treated urgently because of the risk it poses to your remaining vision [5][6]. Understanding why this is happening and what your medical team is doing can help you regain a sense of control.

Why AAION is Addressed Urgently

AAION occurs when the blood supply to your optic nerve (the “cable” that carries visual information from your eye to your brain) is suddenly reduced or blocked [2]. This blockage is most often caused by Giant Cell Arteritis (GCA), also known as temporal arteritis [2].

GCA is a type of vasculitis, which is an inflammation of the blood vessel walls [2]. When these vessels become inflamed, they swell and narrow, eventually restricting the flow of oxygen-rich blood to the eye [2].

Doctors treat this urgently for several reasons:

  • The “Fellow Eye” Risk: Once one eye is affected, ongoing GCA can cause ischemic injury in the “fellow” (other) eye, especially before effective treatment begins [7][8].
  • Long-Term Impact: The vision lost from AAION is usually severe and permanent, although the exact outcome varies depending on the person and the amount of nerve damage [9][10].
  • Rapid Intervention: Starting high-dose medications immediately is the most effective way to calm the inflammation and protect the vision you still have [6][9].

Who is Most Affected?

GCA is most common in older adults, typically over the age of 50, and the risk increases as people reach their 70s and 80s [11]. Women are affected more often than men, and it is most frequently diagnosed in people of Northern European or Scandinavian ancestry [11]. However, it is important to remember that these are population patterns, not rules; GCA can occur in people of any ancestry.

The Medical Response

When your doctors suspect AAION and GCA, they will move quickly. The specific treatment plan depends on your clinical situation. Some patients are admitted to the hospital for intravenous (IV) steroids, while others are prescribed high doses of oral steroid pills [9][12]. Both routes aim to deliver medication to stop the inflammation as fast as possible.

While they treat you, they will also work to confirm the diagnosis using:

  • Blood Tests: They will check for markers of inflammation, such as ESR (erythrocyte sedimentation rate) and CRP (C-reactive protein) [13][14].
  • Imaging or Biopsy: A specialized ultrasound may be used to look at the vessels, or a surgeon may take a small sample from the artery in your temple (temporal artery biopsy) to look for signs of inflammation under a microscope [15][16][8].

Validating Your Experience

It is common for patients with GCA to report a “loss of normality” and intense anxiety about the future of their sight [1]. Research indicates that roughly half of people with GCA experience significant anxiety, and one-third experience depression [17]. These feelings can be even more intense when vision loss is involved [4].

Your medical team should include not just eye and inflammation specialists (ophthalmologists and rheumatologists), but also professionals who can help you adapt to vision changes, such as occupational therapists and low-vision rehabilitation specialists [1][18][19]. Early support, including counseling or peer support groups, can help you manage daily tasks safely and begin the process of emotional recovery [19][20].

Common questions in this guide

Why is arteritic anterior ischemic optic neuropathy an emergency?
Arteritic anterior ischemic optic neuropathy (AAION) is usually caused by giant cell arteritis, which can reduce blood flow to the optic nerve. Vision loss in the affected eye is often severe and permanent, and ongoing inflammation can threaten the other eye, so treatment starts urgently.
Should I start steroids before my AAION tests are complete?
When doctors strongly suspect AAION and giant cell arteritis, they generally start high-dose steroids without waiting for blood tests, imaging, or a temporal artery biopsy. Take the medication exactly as prescribed and do not stop or change it without speaking with your care team.
Which tests can confirm giant cell arteritis after an AAION diagnosis?
Doctors may check ESR, CRP, and platelet counts for signs of inflammation. They may also use a specialized ultrasound or a temporal artery biopsy, in which a small artery sample is examined for inflammation.
How are steroids given for AAION and giant cell arteritis?
Some people are admitted for intravenous steroids, while others receive high-dose oral steroid pills. The route and dose depend on the clinical situation, so your treating team will choose the fastest and safest plan for you.
Can vision lost from AAION return?
Vision lost from AAION is usually severe and permanent because the optic nerve has been injured, although the outcome varies with the amount of damage. The immediate goal of treatment is to reduce inflammation and protect vision in the unaffected eye.
What support is available after vision loss from AAION?
An ophthalmologist and rheumatologist can coordinate medical care, while low-vision rehabilitation specialists and occupational therapists can help you adapt to daily tasks safely. Counseling and peer support may also help with fear, grief, anxiety, or changes in your routine.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.What specifically does my eye exam show that points toward arteritic AION (AAION) rather than other forms of vision loss?
  2. 2.Have my inflammatory markers (like ESR, CRP, and platelets) been checked, and what do they tell us?
  3. 3.What is the immediate plan to protect the vision in my other eye?
  4. 4.What route and dose of steroids is most appropriate for my situation?
  5. 5.When will my temporal artery biopsy or ultrasound be scheduled to confirm the GCA diagnosis?
  6. 6.Who will be the primary doctor coordinating my care?
  7. 7.Can you refer me to a low-vision rehabilitation specialist or occupational therapist right away to help me adapt to my vision changes?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (20)
  1. 1

    What is the impact of giant cell arteritis on patients' lives? A UK qualitative study.

    Liddle J, Bartlam R, Mallen CD, et al.

    BMJ open 2017; (7(8)):e017073 doi:10.1136/bmjopen-2017-017073.

    PMID: 28838902
  2. 2

    Unilateral Central Retinal Artery Occlusion Revealing Giant Cell Arteritis: A Case Report.

    Lazaar H, Moumni A, Aziz A, et al.

    Cureus 2025; (17(3)):e80452 doi:10.7759/cureus.80452.

    PMID: 40225509
  3. 3

    Visual impairment and psychological distress among adults attending the University of Gondar tertiary eye care and training center, Northwest Ethiopia: A comparative cross-sectional study.

    Munaw MB, Tegegn MT

    PloS one 2022; (17(2)):e0264113 doi:10.1371/journal.pone.0264113.

    PMID: 35176097
  4. 4

    Vision-related and health-related quality of life in patients with giant cell arteritis.

    Ní Mhéalóid Á, Conway R, O'Neill L, et al.

    European journal of ophthalmology 2021; (31(2)):727-733 doi:10.1177/1120672120901693.

    PMID: 31957482
  5. 5

    Giant Cell Arteritis.

    Ness T, Nölle B

    Klinische Monatsblatter fur Augenheilkunde 2024; (241(5)):644-652 doi:10.1055/a-2252-3371.

    PMID: 38593832
  6. 6

    Biopsy vs imaging in the diagnosis of giant cell arteritis. Viewpoint 1: in favour of imaging.

    Schmidt WA

    Rheumatology (Oxford, England) 2025; (64(Supplement_1)):i71-i73 doi:10.1093/rheumatology/keae487.

    PMID: 40071427
  7. 7

    Vision loss in giant cell arteritis: case-based review.

    Kokloni IN, Aligianni SI, Makri O, Daoussis D

    Rheumatology international 2022; (42(10)):1855-1862 doi:10.1007/s00296-022-05160-x.

    PMID: 35727336
  8. 8

    Orbital magnetic resonance imaging of giant cell arteritis with ocular manifestations: a systematic review and individual participant data meta-analysis.

    Guggenberger KV, Pavlou A, Cao Q, et al.

    European radiology 2023; (33(11)):7913-7922 doi:10.1007/s00330-023-09770-2.

    PMID: 37256352
  9. 9

    Giant Cell Arteritis: Updates and Controversies.

    Yu E, Chang JR

    Frontiers in ophthalmology 2022; (2()):848861 doi:10.3389/fopht.2022.848861.

    PMID: 38983551
  10. 10

    Characteristics and outcomes of patients with ophthalmologic involvement in giant-cell arteritis: A case-control study.

    Dumont A, Lecannuet A, Boutemy J, et al.

    Seminars in arthritis and rheumatism 2020; (50(2)):335-341 doi:10.1016/j.semarthrit.2019.09.008.

    PMID: 32192630
  11. 11

    Incidence of giant cell arteritis in six districts of Paris, France (2015-2017).

    Gonzalez Chiappe S, Lechtman S, Maldini CS, et al.

    Rheumatology international 2022; (42(10)):1721-1728 doi:10.1007/s00296-022-05167-4.

    PMID: 35819504
  12. 12

    Giant cell arteritis: a closer look at its ophthalmological manifestations.

    Pinto Ferreira NG, Menezes Falcão L, Alves AT, Campos F

    BMJ case reports 2015; (2015()).

    PMID: 26416775
  13. 13

    Population-Based Performance of Inflammatory Markers in Giant Cell Arteritis.

    Castillejo Becerra CM, Crowson CS, Langenfeld HE, et al.

    American journal of ophthalmology 2025; (275()):47-51 doi:10.1016/j.ajo.2025.03.022.

    PMID: 40139650
  14. 14

    Neuro-ophthalmic Manifestations of Giant Cell Arteritis: A Review.

    Khoury JA, Albreiki D

    Journal of ophthalmic & vision research 2025; (20()) doi:10.18502/jovr.v20.15248.

    PMID: 40689118
  15. 15

    Temporal artery biopsy for suspected giant cell arteritis: A mini review.

    Jiang Z, Ji H, Dong J

    Indian journal of ophthalmology 2023; (71(10)):3299-3304 doi:10.4103/IJO.IJO_3163_22.

    PMID: 37787225
  16. 16

    Diagnostic performance of temporal artery ultrasound for the diagnosis of giant cell arteritis: a systematic review and meta-analysis of the literature.

    Rinagel M, Chatelus E, Jousse-Joulin S, et al.

    Autoimmunity reviews 2019; (18(1)):56-61 doi:10.1016/j.autrev.2018.07.012.

    PMID: 30408588
  17. 17

    Measurement of the impact of giant cell arteritis and treatment with glucocorticoids on health-related quality of life.

    Barnes E, Beazer O, Ndosi M, et al.

    Therapeutic advances in musculoskeletal disease 2026; (18()):1759720X261462666 doi:10.1177/1759720X261462666.

    PMID: 42542746
  18. 18

    Developing consensus-based referral criteria for low vision services in Australia.

    Alam K, Connor H, Gentle A, Bentley SA

    Ophthalmic & physiological optics : the journal of the British College of Ophthalmic Opticians (Optometrists) 2022; (42(1)):149-160 doi:10.1111/opo.12902.

    PMID: 34637155
  19. 19

    Low vision home therapy service by occupational therapists: The effectiveness of the Seniors' Eye Rehabilitation programme, a pilot study.

    Tan Y, Sim Tan AC, Hui JHS, et al.

    The British journal of occupational therapy 2023; (86(5)):359-366 doi:10.1177/03080226231153340.

    PMID: 40336517
  20. 20

    Stepped care for depression and anxiety in visually impaired older adults: multicentre randomised controlled trial.

    van der Aa HP, van Rens GH, Comijs HC, et al.

    BMJ (Clinical research ed.) 2015; (351()):h6127 doi:10.1136/bmj.h6127.

    PMID: 26597263

This page explains AAION and GCA, urgent treatment, and diagnostic testing for informational purposes only; it does not constitute medical advice. Follow your care team's instructions and seek urgent help for any new vision changes.

Get notified when new evidence is published on arteritic anterior ischemic optic neuropathy.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.